Skip to content

CROI: New Gilead integrase inhibitor GS-9137 displays potent activity

Experimental HCV protease inhibitor to receive fast track approval

Once-daily arm in maraviroc treatment-naive study terminated

Hepatitis C protease inhibitor does well in early clinical trial

Two integrase inhibitors now making progress in clinical trials

Gilead and BMS to seek regulatory approval for efavirenz, Truvada coformulation

ICAAC: TMC114 shows further promise in second POWER study

ICAAC: Early trials involving new GSK protease inhibitor have encouraging results

ICAAC: Achillion reveals potential for once weekly dosing of nucleoside analogue